Behavioral Changes, Depressed Mood, Hostility, Suicidal Thoughts Reported With Drugs
The U.S. Food and Drug Administration said it will immediately require boxed warnings about the risk of serious neuropsychiatric symptoms on the packaging of two popular smoking cessation drugs -- varenicline (Chantix) and buproprion (Zyban, Wellbutrin and generics).
Reports of behavioral changes, depressed mood, agitation, hostility and suicidal thoughts and behavior associated with use of the drugs have been submitted to the FDA's adverse event reporting system.
Throughout the marketing... Full Story
Contribute | Do you have more information about this topic? If so, please click here to contact the editors of ABC News.
6 Comments | Add Yours
